Pregabalin Capsule
Product Images NDC 70518-4716

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 70518-4716). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Pregabalin Capsule C-V 300 mg oral capsules label from RemedyRepack Inc. The label indicates a quantity of 30 capsules per package, capsule color described as orange/white. It includes federal law caution, storage instructions, and repackager contact information.*

FDA Label Image

Pregabalinfigure1 (Pregabalinfigure1)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at various doses (200 mg, 100 mg, 25 mg three times a day) compared to placebo. The graph depicts decreasing improvement percentages as pain improvement increases along the x-axis.*

FDA Label Image

Pregabalinfigure10 (Pregabalinfigure10)

A line graph comparing the estimated percentage of subjects without LTR (likely a clinical outcome) over a period of 180 days between two groups: Pregabalin and Placebo. The graph shows two curves, with the Pregabalin group maintaining a higher percentage of subjects without LTR over time compared to the Placebo group.*

FDA Label Image

Pregabalinfigure11 (Pregabalinfigure11)

A line chart comparing the percent of subjects improved over time from baseline to week 12, as measured by BOCF. The x-axis represents percent improvement from baseline to week 12, ranging from 0 to 100, and the y-axis shows the percent of subjects improved, ranging from 0 to 100. Two lines are plotted: a solid line for Pregabalin and a dotted line for Placebo, showing higher improvement percentage in the Pregabalin group.*

FDA Label Image

Pregabalinfigure12 (Pregabalinfigure12)

A line graph depicting the percentage of subjects improved from baseline to Week 16 BOCF. The x-axis shows the percent improved from 0% to 100%, and the y-axis indicates the percent of subjects improved from 0% to 100%. Two lines are presented: a solid line for Pregabalin and a dotted line for Placebo, showing a higher improvement percentage for Pregabalin compared to Placebo over the range.*

FDA Label Image

Pregabalinfigure2 (Pregabalinfigure2)

A line graph comparing the percent of patients improved against the percent improvement in pain from baseline. It shows two curves: one for Pregabalin 100 mg administered three times a day and another for placebo, illustrating patient improvement rates.*

FDA Label Image

Pregabalinfigure3 (Pregabalinfigure3)

A line graph showing percent of patients improved relative to percent improvement in pain from baseline. It compares four groups: Pregabalin 300 mg twice a day, Pregabalin 150 mg twice a day, Pregabalin 75 mg twice a day, and placebo, with Pregabalin 300 mg showing the highest patient improvement rates.*

FDA Label Image

Pregabalinfigure4 (Pregabalinfigure4)

A line graph illustrating the percentage of patients improved against percent improvement in pain from baseline. The graph compares three groups: Pregabalin 200 mg three times daily, Pregabalin 100 mg three times daily, and a placebo, showing patient improvement trends over stated pain improvement percentages.*

FDA Label Image

Pregabalinfigure5 (Pregabalinfigure5)

A line chart showing the percent of patients improved versus percent improvement in pain from baseline. It compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo. The chart demonstrates higher patient improvement percentages with Pregabalin dosages compared to placebo.*

FDA Label Image

Pregabalinfigure6 (Pregabalinfigure6)

A bar chart comparing responder rates (%) across different dosages in two studies labeled Study E1 and Study E3. The x-axis shows treatment groups including placebo and various daily doses of the drug, while the y-axis shows responder rate percentages from 0 to 60%. Study E1 includes placebo and doses from 50 mg/day to 600 mg/day with BID dosing, and Study E3 includes placebo and 600 mg/day with BID and TID dosing. An asterisk indicates statistical significance versus placebo.*

FDA Label Image

Pregabalinfigure7 (Pregabalinfigure7)

A line graph showing median percent change from baseline in seizure reduction plotted against daily dose (mg/day) for four different studies labeled E1 B1D, E2 T1D, E3 B1D, and E3 T1D. Data points indicate increasing seizure reduction with higher doses up to 600 mg/day, with p-values denoting statistical significance at various doses. Placebo dose is indicated as zero on the x-axis.*

FDA Label Image

Pregabalinfigure8 (Pregabalinfigure8)

A bar chart showing responder rates (%) for three groups: Placebo (22.6%, n=93), 2.5 mg/kg/day dosage (29.1%, n=103), and 10 mg/kg/day dosage (40.6%, n=96). The Y-axis represents responder rate percentages, and the X-axis lists the treatment groups with corresponding sample sizes.*

FDA Label Image

Pregabalinfigure9 (Pregabalinfigure9)

A line chart displaying the percentage of patients improved versus percent improvement in pain from baseline. The graph compares Pregabalin at 600 mg, 450 mg, 300 mg daily doses, and placebo, showing trends of pain improvement among patient groups over the pain improvement scale from 0 to 100 percent.*

FDA Label Image

Pregabalinstructure (Pregabalinstructure)

Chemical structure of Pregabalin illustrating its molecular formula with an amine group (NH2), a carboxylic acid group (COOH), and a side chain including a methyl group (CH3). The structure highlights the arrangement of atoms relevant to the active ingredient Pregabalin.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.